{"uid":"cap_Pvo283bdyIrWSrxu0HcZR","slug":"bnm-data-shop-swisspar-first-authorisations-6e438083","name":"BNM Data Shop – SwissPAR First Authorisations","description":"Official public data as JSON. Unpaid paid routes return HTTP 402.","url":"https://ticks.bnm.farm/swisspar","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"headers":{"type":"object","additionalProperties":{"type":"string"}},"queryParams":{"type":"object","additionalProperties":{"type":"string"}}},"additionalProperties":false},"output":{"type":"object","properties":{"type":{"type":"string"},"schema":{"type":"object"},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"ok":true,"asOf":"2026-08-18","cards":[{"id":"rhapsido-70227","ma":"70227","inn":"remibrutinib","body":"Swiss Public Assessment Report\nRhapsido\nInternational non-proprietary name: remibrutinib\nMarketing authorisation no.: 70227","date":"2026-08-18","name":"Rhapsido","holder":"Novartis Pharma Schweiz AG","sourceUrl":"https://www.swissmedic.ch/dam/swissmedic/en/dokumente/zulassung/swisspar/70227-rhapsido-01-swisspar-20280818.pdf.download.pdf/SwissPAR_inkl.%20FI_Rhapsido.pdf"}],"source":"https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/authorisations/swisspar.html","status":"ok","product":"swisspar-first-auth","records":[{"id":"rhapsido-70227","url":"https://www.swissmedic.ch/dam/swissmedic/en/dokumente/zulassung/swisspar/70227-rhapsido-01-swisspar-20280818.pdf.download.pdf/SwissPAR_inkl.%20FI_Rhapsido.pdf","date":"2026-08-18","firm":"Novartis Pharma Schweiz AG","type":"swisspar"}],"fetchedAt":"2026-08-23T12:00:00.000Z","recordCount":1}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.05","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.05/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.05","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.05","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_ON2bVRrT0eEMgrrldAdQC","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.05","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Returns Swiss Public Assessment Reports (SwissPAR) for newly authorised human medicines as structured JSON, sourced from Swissmedic's official portal.","exampleAgentPrompt":"Can you pull the latest SwissPAR first-authorisation records from Swissmedic and give me the brand names, INNs, authorisation numbers, and holder companies as structured data?","exampleUseCases":[{"title":"Pharma competitive intelligence briefing","prompt":"Get me all the newly first-authorised drugs listed on Swissmedic's SwissPAR page, including their brand names, INNs, marketing authorisation numbers, and the companies that hold them — I want to track new Swiss market entrants."},{"title":"Regulatory affairs PDF retrieval","prompt":"I need the source PDF links for every SwissPAR first-authorisation record available from Swissmedic so I can download and review the full assessment reports for our regulatory dossier."},{"title":"Drug approval date lookup","prompt":"What's the official first-authorisation date and marketing authorisation holder for remibrutinib (Rhapsido) according to the Swissmedic SwissPAR records?"}],"resultDescription":"A JSON object containing: an 'ok' boolean, an 'asOf' date string, a 'cards' array and a 'records' array (each record has id, marketing authorisation number, INN, brand name, holder company, source PDF URL, date, and record type), plus metadata fields including source URL, product identifier, fetchedAt timestamp, status string, and total recordCount.","failureModes":["HTTP 402 if payment is not provided or payment fails — endpoint requires $0.05 USDC per call via x402 protocol","Empty records array if Swissmedic has not published any new first-authorisation SwissPARs recently","Stale 'asOf' date if Swissmedic source page has not been updated","Network timeout if upstream Swissmedic site is temporarily unavailable","Malformed response if the Swissmedic HTML structure changes and parsing breaks"],"whenToPreferThis":"Choose this endpoint when you need Swissmedic SwissPAR first-authorisation data as clean, structured JSON without building your own scraper for the Swissmedic website. It is ideal for pharmaceutical researchers, regulatory affairs professionals, and competitive intelligence workflows that need programmatic access to Swiss drug approval records including INN-to-brand mappings, holder company names, authorisation numbers, and direct links to official PDF assessment reports.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-15T13:01:20.522Z","isFirstParty":false}